**ATLAS: A Phase 2, Open-Label Trial of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma**

Petros Grivas, Min Yuen Teo, Nicholas Vogelzang, Ajai Ah, Youssef Zakharia, Nabil Adra, Adriana Drakaki, Farin Husain, Rafael Morales-Barrera, Andrea Necchi, Alejandro Rodriguez-Vida, Susan Feyderab, Lamia Gupta, Debra H. Joseph, Yohann Loriot, Alexander Drakaki, Alexandra Drakaki, Loriot, All patients to be followed for tumor tissue and circulating tumor DNA for biomarker testing, and MTX, oral capecitabine; BID, twice daily; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HRD, homologous recombination deficiency; mHCT, myelohematologic cell transplantation; mCRC, metastatic colon cancer; mUC, metastatic urothelial cancer; NGS, next-generation sequencing; OS, overall survival; PD, progressive disease; RECIST, Response Evaluation Criteria in Solid Tumors; RUC, rucaparib; SD, stable disease; TDR, tumor death ratio; W, week.

**INTRODUCTION**

- There are limited treatment options for patients with metastatic urothelial carcinoma who have progressed on platinum-based chemotherapy, and there is a critical need for novel agents to treat patients with platinum or carboplatin-cisplatin-based chemotherapy and/or immune checkpoint inhibitor therapy.

**ATLAS TRIAL OVERVIEW**

- **ATLAS** (NCT02338088; EudraCT 2017-004100-10; EudraCT2017-004100-10) is an international, open-label, phase 2 trial designed to evaluate single-agent rucaparib (300 mg twice daily) as treatment for locally advanced or metastatic urothelial carcinoma.

- **Eligibility criteria**:
  - Patients ≥ 18 years of age with histologically confirmed urothelial carcinoma that is locally advanced or metastatic who are not candidates for curative-intent surgery or radiation therapy.
  - Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–1.
  - No prior systemic therapy for metastatic disease.
  - No prior history of aplastic anemia.

- **Study population**: Approximately 200 patients will be enrolled at 65 sites in 6 countries.

**BIOMARKER ASSESSMENT**

- The ATLAS trial design was originally presented at the ASCO Annual Meeting 2018. This biomarker analysis represents information available at the time of the initial presentation. The results presented here are from NGS testing of tumor samples.